Practical Aspects of Incorporating CAR T-Cell Therapy into Your Practice

Release Date: September 9, 2021
Expiration Date: September 9, 2022

Activity Overview
Hear what Dr. Sagar Lonial and Dr. Loretta Nastoupil have to say as they highlight the most up-to-date information and provide key takeaways on caring for patients with CAR T-cell therapy from an independent satellite symposium held following the #ASCO21 meeting.  

Target Audience
The target audience for this activity is c
ommunity and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.

Learning Objectives
After participating in this activity, participants should be better able to:

  • Incorporate CAR T cell therapy into their clinical practice and identify appropriate patients
  • Develop strategies to mitigate treatment-related adverse events that may occur during treatment with CAR T cell therapy
  • Discuss the emerging results of clinical trials that are investigating CAR T cell therapies in lymphoma and myeloma
  • Optimize the referral process and multidisciplinary care for patients who qualify for CAR T Cell therapy

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Consultant Fees: Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC., Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Loretta Nastoupil, MD
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine
Director, Lymphoma Outcomes Database, Department of Lymphoma/Myeloma, Division of Cancer Medicine
Section Chief, New Drug Development, Department of Lymphoma/Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Fees: Celgene, Genentech, Gilead/Kite, Janssen, Novartis, Pfizer Inc., Takeda Pharmaceutical Company, TG Therapeutics
Contracted Research: Celgene, Epizyme, Inc., Genentech, Gilead/Kite, Janssen, Merck & Co., Novartis, Pfizer Inc., Takeda Pharmaceutical Company

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This activity is supported by independent educational grants from Janssen Scientific Affairs, LLC and Legend Biotech.

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.